Nikhil Munshi, MD, on Using Ciltacabtagene Autoleucel in Treating Relapsed or Refractory Multiple Myeloma: Clinical Considerations

Posted: Friday, September 1, 2023

Nikhil Munshi, MD, of Dana-Farber Cancer Institute, discusses the clinical implications of the updated efficacy and safety data on ciltacabtagene autoleucel for heavily pretreated patients with multiple myeloma. He explores the process of preparing for infusion of this immunotherapy, both for patients and providers, monitoring patients after infusion, and managing related toxicities.

---